Search results
Results from the WOW.Com Content Network
The H 2 receptor antagonists are a class of drugs used to block the action of histamine on parietal cells in the stomach, decreasing the production of acid by these cells. H 2 antagonists are used in the treatment of dyspepsia, although they have been surpassed in popularity by the more effective [1] proton pump inhibitors.
H 2 antagonists can be used in the treatment of dyspepsia, peptic ulcers and gastroesophageal reflux disease. They have been surpassed by proton pump inhibitors (PPIs). The PPI omeprazole was found to be more effective at both healing and alleviating symptoms of ulcers and reflux oesophagitis than the H 2 blockers ranitidine and cimetidine. [2]
These infections can include Helicobacter pylori due to this species not favouring an acid environment, leading to an increased risk of ulcers and gastric cancer risk in genetically susceptible patients. [50] PPI use in people who have received attempted H. pylori eradication may also be associated with an increased risk of gastric cancer. [51]
“High blood pressure can damage blood vessels in the brain, leading to vascular issues that increase dementia risk,” says Smita Patel, D.O., FAASM, a board-certified neurologist with Endeavor ...
Older patients are at a higher risk of experiencing CNS side effects. [citation needed] The link possible between anticholinergic medication use and cognitive decline/dementia has been noted in weaker observational studies. [21]
A link between these types of drugs and cognitive impairment isn't a totally new discovery, but for the first time, researchers used brain imaging techniques to determine the physical changes ...
In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively clearing up 'waste', though it remains unclear whether this could affect ...
Sucralfate may be considered to have the advantage over H2-blockers and PPIs in this regard because sucralfate does not change the pH of gastric fluid. A majority of meta-analyses found that sucralfate therapy decreased the incidence of ventilator-associated pneumonia compared to H2-antagonists. [10]